Nelson Advisors Big Questions in HealthTech Series: Is Venture Capital right for MedTech? Should more European MedTech be funded by debt, royalties or strategics from day one?
NA
The financing of European medical technology is undergoing a structural transition that challenges the viability of its historical funding mechanisms. For decades, early-stage medtech innovation relied on the traditional venture capital model, which was originally pioneered to support the rapid scaling, high gross margins and predictable, capital-efficient exit pathways of the software industry.
However, the combination of physical hardware development timelines, complex and localised national reimbursement frameworks, and the operational demands of the EU Medical Device Regulation (MDR) has exposed a fundamental mismatch between the investment horizon of venture capital and the development cycles of modern medical technologies.
This mismatch is reflected in a severe contraction in growth-stage venture capital. While early-stage seed and Series A valuations have shown nominal resilience, the volume of capital available for subsequent rounds has collapsed. Total investment in growth-stage healthcare in late 2024 was 84% lower than its peak in late 2021, creating a severe supply-demand bottleneck as a surplus of Series A companies compete for a dwindling pool of follow-on growth capital. This venture funding gap is compounded by a dramatic decline in fundraising. Early-stage life sciences venture fundraising plummeted by over 80% from 2021 to 2022, and despite a partial rebound, it remains 46% below 2021 levels, meaning that the "dry powder" accumulated during the pandemic boom has been largely exhausted. At the same time, regulatory changes under the Capital Requirements Regulation (CRR) and Capital Requirements Directive (CRD) have raised the cost of bank investments in private equity and venture capital funds, further restricting the flow of institutional capital into high-risk asset classes.
Consequently, the European medtech ecosystem has entered an era of "industrial maturity". This phase is characterised by a departure from the "growth at all costs" paradigm that defined the zero-interest-rate policy (ZIRP) era. Valuation metrics have shifted from speculative user-acquisition numbers to strict fundamentals, clinical validation, unit economics, and risk-mitigated regulatory positioning. To maintain global competitiveness, European medtech must evaluate alternative capital formation strategies.
Conclusion
Venture capital is a mismatched financial instrument when applied as a single source of capital across the entire medtech development lifecycle. The structural friction of the EU MDR, combined with localised reimbursement fragmentation and incompressible clinical timelines, has broken the traditional venture capital "escalator" in Europe.
However, the proposal to fund medtech from "day one" utilising debt or royalties is a structural impossibility due to the underwriting standards of these credit and yield-based instruments.
The solution for European medtech is the construction of a diversified capital stack. Founders must sequence public non-dilutive grants and tax incentives to fund early-stage R&D; transition to patient, evergreen family offices and strategic corporate venture capital to navigate clinical validation and regulatory review; and unlock venture debt, private credit and synthetic capped royalties only after securing regulatory clearance and establishing commercial revenue visibility.
By re-engineering the capital stack to match capital structures with underlying asset risk, European medtech can bypass the growth equity bottleneck, preserve founder equity, and bring clinical innovations to patients globally.
Click here to read the report in full https://www.healthcare.digital/single-post/nelson-advisors-big-questions-in-healthtech-series-is-venture-capital-right-for-medtech-should-mor
Nelson Advisors > European MedTech and HealthTech Investment Banking
Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk
Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital
Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb
Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk
#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech
Nelson Advisors LLP
Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT
[email protected]
Meet Nelson Advisors @ 2026 Events
Digital Health Rewired > March 2026 > Birmingham, UK
NHS ConfedExpo > June 2026 > Manchester, UK
HLTH Europe > June 2026, Amsterdam, Netherlands
HIMSS AI in Healthcare > July 2026, New York, USA
Bits & Pretzels > September 2026, Munich, Germany
World Health Summit 2026 > October 2026, Berlin, Germany
HealthInvestor Healthcare Summit > October 2026, London, UK
HLTH USA 2026 > October 2026, USA
Barclays Health Elevate > October 2026, London, UK
Web Summit 2026 > November 2026, Lisbon, Portugal
MEDICA 2026 > November 2026, Düsseldorf, Germany
Venture Capital World Summit > December 2026 Toronto, Canada